Persistent Pulmonary Hypertension of Newborn
8
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness
Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn
Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns
Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure
Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study
N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension
Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients
Nitro Oxide Inhalation Continued With Sildenafil on Neonatal Persistent Pulmonary Hypertension